Member Info for Riesgo

It’s difficult to move on but I’ve taken a significant loss and now all into travel stocks, looking to recover my losses. I hope to be back in when Jupiter decide to leave us and good news is available on the cancer drugs. The last straw was realising my belief in quick adaptation of our LFD to new variants was false. Affimers being quicker and cheaper than competitor’s antibodies. A crock of lies.

Where is the research Q? I can only see an extract from the recent RNS.

Sorry, if already discussed, but I'm not clear on if AVA6k is ahead of schedule or not.

End of November RNS said;
The FDA has completed its 30-day review of Avacta's IND application, which was submitted ahead of schedule in October 2021, and has concluded that the Group may proceed with its proposed clinical investigation. This allows Avacta to enroll eligible patients into US clinical trial sites for the company's Phase I multi-centre study, ALS-6000-101. As previously announced in August 2021, the Company has begun recruiting and dosing patients for this study at several clinical trial sites in the UK, and continues to expect the dose escalation phase for this trial to complete by Q2 2022 followed by completion of the dose expansion phase around mid-2023. Enrollment in US clinical trial sites is expected to begin in early 2022.

Presumably we will hear about enrollment in the US clinical trials shortly.

I keep asking myself, what does AS really want. Would he like to return to a comfortable Uni post one day? Would he like to be rich beyond his wildest dreams and recognised as a major contributor to improving the health of many? Then my next question is, how can you achieve his ambitions? A great new cancer treatment would be a good start, then he needs to prove it works, get a few financial people to drive up its value and then sell to the highest bidder who will drive his drugs faster and harder.

C3 what on Earth makes you believe I think that?
I totally agree.
Are you misreading what I’ve said.

What’s not true C3? Surely it will be the benefit beyond the normal dose that will be of interest, which could be more or less, as you say. An important marketing point introduced by the trials will be the a tolerated dose difference from the normal dose. I very much doubt anyone will make a comparison with, or be interested in, the initial dose of the first trial.

Spart - no one is disagreeing it’s 50% above the initial dose as far as I can see. So why do you keep banging on about it? It’ll be the benefit realised above the normal dose that will be used to market the product. No one will mention the initial dose.

Spartacus - there is indeed nothing hard to see. Just insignificant confusion caused by sloppy use of certain words by some, including yourself.

Spartacus - the issue of different percentages is due to some people saying ‘standard’ or ‘normal’ when they meant to say ‘initial’. They should start their research reading a dictionary.

90 to 120 = 33%

My money is on preparing for a buy out by someone who will provide AS and his team with rocket boosters to get all the other cancer drugs to market as quickly as possible.

Remember it is advertised as a “post trading update” roadshow.
That’s not my recollection Penny. Where did you read this?

Extra cash when you don’t really need it allows rapid expansion or acquisitions. Sounds positive to me.

We all know AS heart is in Cancer drugs.
Hold a road show for institutional investors if AVA6000 results were looking brilliant and you were expecting to attract a buy out? A buy out that could help you fast track all other cancer drugs and complete your dreams. Would you want institutional investors to pump up the price to make the most or your shares before the inevitable buy out?

Hold a road show for institutional investors if AVA6000 results were looking brilliant and you were expecting to attract a buy out? A buy out that could help you fast track all other cancer drugs and complete your dreams. Would you want institutional investors to pump up the price to make the most or your shares before the inevitable buy out?

A reliable test could still help schools, especially those with 50% staff isolating at home.
One in eight pupils out of school as Covid worsens https://www.bbc.co.uk/news/education-60126783

Top Man & Woman.
Thanks for sharing Ruth.

The world urgently needs a reliable LFT. Thank goodness Avacta is on the job.

I’ve not been right since before new year. Sore throat, coughing occasionally and fatigue. Seven negative LFTs. Mixture of AffiDX, FlowFlex and Innova. I’m fully vaccinated. Phoned Doctor and Receptionist says get a PCR test because loads of patients with similar symptoms have also tested negative with LFTs but positive with PCR. She said it’s frightening to think that lots of people are testing negative with LFTs and then carrying on without isolating.

But no other LFT has declared itself not fit for purpose, even though they also depend on antibodies. So who is going to be quickest back to market? The one in pole position or the ones still in the pits. And who’s LFT will secure the most confidence it is fit for purpose?